Scientists of the Institute of Medical Virology in Frankfurt am Main (Germany) conducted a study of the antiviral effect of the drug against SARS-COV-2 virus in a cell model. The drug was tested on human cells infected with SARS-COV-2 Enisamium showed a good effect. This was the reason for starting clinical trials of the drug in Ukraine.
Upon successful completion of the tests, Amizon will be available in all countries where Farmak is present.
Clinical trials will last several months.
“Amizon” as an effective drug for the treatment of influenza and other SARS is already bought by patients in 11 countries – including Belarus, Kazakhstan, Uzbekistan and others.
The pharmaceutical company JSC “Farmak” considers the possibility of launching the manufacture of products, in particular, diagnostic test kits, to combat coronavirus spread. “Now we analyse the possibility of arranging the release of supportive care products, disinfectants and antiseptics, diagnostic test kits, protective medical products, including masks, ...
Farmak searches for engaging startups in the innovative medical technology market in cooperation with Sector X. “Why are we here? To find new business development points in P4 (predictive, preventive, personalized and participatory) medicine. Admittedly, the corporate sector may effectively operate a customized business model, but it is cumbersome enough to ...
According to “Business” magazine, JSC “Farmak” is ranked among the TOP 5 companies of Ukraine in the nomination “Strong Top Management – Dream Team”. The foundation of strong and modern business is its staff component. People, their development, professionalism are the core values of “Farmak”. “We have more than 2500 employees. We fill more than […]